May 18 (Reuters) - Biotherapeutics company CSL Ltd CSL.AX on Friday lifted its full-year profit guidance for a second time this year, thanks to better-than-expected product sales.
CSL now expects net profit after tax for fiscal 2018 in the range of about $1.68 billion to $1.71 billion, from an earlier forecast of $1.55 billion to $1.60 billion, it said in a statement.